Immunotherapy drug shows favorable safety profile in patients with advanced small cell lung cancer – News-Medical.net
|
Immunotherapy drug shows favorable safety profile in patients with advanced small cell lung cancer
News-Medical.net The immunotherapy drug pembrolizumab has demonstrated a favorable safety profile and "promising durable clinical activity" in pretreated patients who exhibit high levels of the PD-L1 protein in advanced stages of small cell lung cancer (SCLC) – an … |
